1. P373 Psoriasis and psoriasiform skin lesions in patients with Inflammatory Bowel Disease treated with infliximab: a pharmacokinetic analysis. (27th May 2021) Authors: Rodrigues, I; Damião, F; Serrazina, J; Fernandes, S; Bernardo, S; Gonçalves, A R; Moura Santos, P; Baldaia, C; Valente, A; Correia, L; Tato Marinho, R Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S390 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P510 Comparative effectiveness of Ustekinumab against other biologics in Inflammatory Bowel Disease: a propensity score analysis. (30th January 2023) Authors: Matos Coelho Bernardo, S; Fernandes, S; Serrazina, J; Rodrigues, I; Botto, I; Bronze, S; Gonçalves, A R; Valente, A; Santos, P M D; Tato Marinho, R; Correia, L Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i640 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P532 Proactive therapeutic drug monitoring improves clinical outcomes in patients with inadequate post-induction infliximab trough levels. (21st January 2022) Authors: Botto, I; Coelho Rodrigues, I; Serrazina, J; Fernandes, S; Bernardo, S; Gonçalves, A R; Moura Santos, P; Valente, A; Correia, L; Tato Marinho, R Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i484 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P586 Surgical recurrence in Crohn's Disease: Can we prevent it?. (21st January 2022) Authors: Botto, I; Serrazina, J; Coelho Rodrigues, I; Fernandes, S; Bernardo, S; Gonçalves, A R; Moura Santos, P; Valente, A; Correia, L; Tato Marinho, R Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i524 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P614 Proactive infliximab is superior to either conventional infliximab and vedolizumab in Inflammatory Bowel Disease. (21st January 2022) Authors: Rodrigues, I; Serrazina, J; Botto, I; Fernandes, S; Bernardo, S; Gonçalves, A R; Moura Santos, P; Valente, A; Correia, L; Tato Marinho, R Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i543 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗